ELECTRONIC SUPPLEMENTARY MATERIAL

Early and Sustained Improvements in Symptoms and Quality of Life With Upadacitinib in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: 52-Week Results From 2 Phase 3 Randomized Clinical Trials (Measure Up 1 and Measure Up 2)

Jonathan I. Silverberg,[1] Melinda J. Gooderham,[2-4] Amy S. Paller,[5] Mette Deleuran,[6] Christopher G. Bunick,[7] Linda F. Stein Gold,[8] DirkJan Hijnen,[9] Brian M. Calimlim,[10] Wan-Ju Lee,[10] Henrique D. Teixeira,[10] Xiaofei Hu,[10] Shiyu Zhang,[10] Yang Yang,[10] Ayman Grada,[10] Andrew M. Platt,[10] Diamant Thaçi[11]

[1]Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA
[2]Skin Centre for Dermatology, Peterborough, Ontario, Canada
[3]Department of Medicine, Queen's University, Kingston, Ontario, Canada
[4]Probity Medical Research, Waterloo, Ontario, Canada
[5]Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
[6]Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark
[7]Department of Dermatology, Yale University, New Haven, CT, USA
[8]Henry Ford Health System, Detroit, MI, USA
[9]Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
[10]AbbVie Inc., North Chicago, IL, USA
[11]Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany

Corresponding Author:
Name: Jonathan I. Silverberg, MD, PhD, MPH
Email address: jonathanisilverberg@gmail.com

Content

Supplemental Table 1 Pre-defined MCID and minimal disease burden threshold scores for reported PRO measures

PRO	MCID[a]	Minimal disease burden threshold score[b]
WP-NRS[c]	≥ 4-point improvement	0 or 1[d]
POEM[e]	≥ 4-point improvement	0–2[f]
DLQI	≥ 4-point improvement	0 or 1[g]
ADerm-SS Skin Pain[c,e]	≥ 4-point improvement	0 or 1[d]
ADerm-SS TSS-7[e]	≥ 28-point improvement	0–11[d]
ADerm-IS Sleep[c,e]	≥ 12-point improvement	0–3[d]
ADerm-IS Emotional State[e]	≥ 11-point improvement	0–2[d]
ADerm-IS Daily Activities[e]	≥ 14-point improvement	0–2[d]
PGIS[h]	—	"absent" or "minimal"
PGIC[i]	—	"very much improved" or "much improved"
PGIT[j]	—	"extremely satisfied" or "very satisfied"

AD atopic dermatitis, *ADerm-IS* Atopic Dermatitis Impact Scale, *ADerm-SS* Atopic Dermatitis Symptom Scale, *DLQI* Dermatology Life Quality Index, *MCID* minimal clinically important differences, *PGIC* Patient Global Impression of Change, *PGIS* Patient Global Impression of Severity, *PGIT* Patient Global Impression of Treatment POEM Patient-Oriented Eczema Measure, *PRO* patient-reported outcome, *TSS-7* 7-item total symptom score, *WP-NRS* Worst Pruritus Numerical Rating Scale

[a]MCID-based endpoints were assessed among patients with a baseline score greater than or equal to the MCID value

[b]Minimal disease burden endpoints were assessed among patients with a baseline score greater than the minimal disease burden threshold score

[c]Up to week 16, endpoints were assessed daily and were reported as the weekly rolling average. Values were rounded to the nearest integer when determining the achievement of the minimal disease burden threshold score

[d]Threshold score interpreted as "no or minimal" impact of AD on itch, skin pain, skin symptoms, sleep, emotional state, or daily activities

[e]Absolute threshold scores were assessed post hoc

[f]Threshold score interpreted as "clear or almost clear" skin

[g]Threshold score interpreted as "no" impact of AD on quality of life

[h]Overall AD symptom severity assessed on a 7-level scale ranging from a score of 0 ("absent") to 6 ("very severe")

[i]Overall change in AD symptoms assessed on a 7-level scale ranging from a score of 1 ("very much improved") to 7 ("very much worse")

[j]Overall level of satisfaction/dissatisfaction with current treatment for AD assessed on a 7-level scale ranging from 1 ("extremely dissatisfied") to 7 ("extremely satisfied")

Fig. S1 Improvement in itch (OC).[a] **a** WP-NRS (LS mean percent change from baseline). **b** SCORAD itch (LS mean percent change from baseline). Error bars indicate 95% confidence interval. [a]Assessed daily through week 16, and reported as the weekly average; assessed at scheduled visits thereafter. *LS* least squares, *OC* observed case, *PBO* placebo, *SCORAD* SCORing Atopic Dermatitis, *UPA* upadacitinib, *WP-NRS* Worst Pruritus Numerical Rating Scale





Fig. S2 Improvement in pain and other skin symptoms (OC). **a** ADerm-SS Skin Pain (LS mean percent change from baseline).[a] **b** ADerm-SS TSS-7 (LS mean percent change from baseline). **c** POEM (LS mean percent change from baseline). Error bars indicate 95% confidence interval. [a]Assessed daily through week 16, and reported as the weekly average; assessed at scheduled visits thereafter. *ADerm-SS* Atopic Dermatitis Symptom Scale, *DLQI* Dermatology Life Quality Index, *LS* least squares, *OC* observed case, *POEM* Patient-Oriented Eczema Measure, *PBO* placebo, *TSS-7* 7-item total symptom score, *UPA* upadacitinib



Fig. S3 Improvement in sleep (OC). **a** ADerm-IS Sleep (LS mean percent change from baseline).[a] **b** SCORAD sleep (LS mean percent change from baseline). **c** POEM sleep 0.[b] Error bars indicate 95% confidence interval. [a]Assessed daily through week 16, and reported as the weekly average; assessed at scheduled visits thereafter. [b]Assessed in patients with POEM sleep > 0 at baseline. *ADerm-IS* Atopic Dermatitis Impact Scale, *LS* least squares, *OC* observed case, *POEM* Patient-Oriented Eczema Measure, *PBO* placebo, *SCORAD* SCORing Atopic Dermatitis, *UPA* upadacitinib



Fig. S4 Improvement in daily living, daily activities, and emotional state (OC). **a** DLQI (LS mean percent change from baseline). **b** CDLQI 0/1.[a] **c** CDLQI (LS mean percent change from baseline). **d** ADerm-IS Daily Activities (LS mean percent change from baseline). **e** ADerm-IS Emotional State (LS mean percent change from baseline). Error bars indicate 95% confidence interval. [a]Assessed in patients with CDLQI > 1 at baseline. *ADerm-IS* Atopic Dermatitis Impact Scale, *CDLQI* Children's Dermatology Life Quality Index, *DLQI* Dermatology Life Quality Index, *LS* least squares, *OC* observed case, *PBO* placebo, *UPA* upadacitinib



Fig. S5 Improvement in anxiety and depression (OC). HADS-A < 8 and HADS-D < 8.[a] Error bars indicate 95% confidence interval. [a]Assessed in patients with HADS-A ≥ 8 or HADS-D ≥ 8 at baseline. *HADS-A* Hospital Anxiety and Depression Scale–Anxiety, *HADS-D* Hospital Anxiety and Depression Scale–Depression, *OC* observed case, *PBO* placebo, *UPA* upadacitinib



Fig. S6 Patient global impressions through 52 weeks of upadacitinib treatment (OC). **a** PGIS[a] "minimal" or "absent." **b** PGIC "very much improved" or "much improved." **c** PGIT[b] "extremely satisfied" or "very satisfied." Error bars indicate 95% confidence interval. [a]Assessed in patients without "absent" or "minimal" symptoms at baseline. [b]Assessed in patients who were not "very satisfied" or "extremely satisfied" at baseline. *OC* observed case, *PBO* placebo, *PGIC* Patient Global Impression of Change, *PGIS* Patient Global Impression of Severity, *PGIT* Patient Global Impression of Treatment, *UPA* upadacitinib